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Abstract: Objectives: The objective of this study was to identify and examine ICD utilization in a large group of eligible 
coronary artery bypass grafting (CABG) patients with impaired left ventricular function.  
Methods: We conducted a retrospective study of ICD eligible patients who had previously undergone CABG surgery  
between March 1, 1995 and June 30, 2008 at a single tertiary care institution. All patients with a pre-operative left  
ventricular ejection fraction (LVEF)  35% were considered ICD eligible. The events of interest were ICD implantation 
and mortality, based on administrative data linkage.  
Results: A total of 1,169 out of 11,931 CABG patients operated on during the same period had LVEF  35% and were  
defined as ICD eligible (mean EF = 27.3% +/- 6.4%). Of these eligible patients, only 101 received an ICD during follow-
up (8.6%). The median time to implant was 255 days (14-1078). The single variable that independently predicted eventual 
ICD implantation was a history of arrhythmia (OR = 7.4; CI, 4.4-12.2). The variables that predicted not having an ICD 
implanted during follow-up included the need for urgent CABG (OR = 0.5; CI, 0.2-0.9), age > 70 years (OR = 0.5; CI, 
0.3-0.8), female gender (OR = 0.2; CI,0.1-0.6), or having chronic obstructive lung disease (OR = 0.5; CI,0.3-0.8). As a 
data validation step, a series of consecutive patient records were reviewed (n=80) showing that fewer than 23% underwent 
appropriate follow-up EF assessment post revascularization. 
Conclusion: Our findings suggest that CABG patients with ischemic cardiomyopathy have low rates of ICD utilization. 
This is particularly evident among females and elderly patients. Furthermore our data suggests that few patients post-
revascularization undergo follow-up EF assessment despite current guidelines likely contributing to the low rates of ICD 
utilization. 
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BACKGROUND 
  Implantable cardioverter-defibrillator (ICD) devices have 
played a key role in anti-arrhythmic intervention. These de-
vices are currently used for the prevention of fatal arrhyth-
mias, particularly in patients with ischemic disease [1]. His-
torically, ICD devices were used solely for the secondary 
prevention of recurrent ventricular fibrillation (VF) and ven-
tricular tachycardia (VT) [1-4]. However, the indication for 
ICD implantation has evolved over the past decade to in-
clude the prevention of potentially lethal arrhythmias in pa-
tients with ventricular dysfunction who are otherwise asymp-
tomatic [5-8]. This shift towards primary prevention was due 
in large part to the findings of several large randomized con-
trol trials, which have reported significant mortality risk re-
duction with the prophylactic use of ICD therapy [5, 6, 8-
10].  
  Current Canadian Cardiovascular Society (CCS) recom-
mendations state that prophylactic ICD therapy should be 
considered for patients with ischemic heart disease with   
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or without mild to moderate heart failure symptoms and a 
reduced left ventricular ejection fraction (LVEF). Ejection 
fraction should be measured at least 1 month after myocar-
dial infarction (MI) and at least 3 months following coronary 
revascularization (class I, level A). ICD therapy may also be 
considered in patients with non-ischemic cardiomyopathy 
present for at least 9 months, New York Heart Association 
(NYHA) functional class II to III heart failure, and an LVEF 
 30% (class IIa, level B) or an LVEF of 31% to 35% (class 
IIb, level C). Additionally, an ICD may be considered in 
patients with ischemic heart disease, previous MI, LV dys-
function (LVEF of 31% to 35%) measured at least 1 month 
after MI and 3 months after coronary revascularization and 
with inducible VF / sustained VT at electrophysiology study 
(class IIa, level B), or without an electrophysiology study 
(class IIb, level C evidence) [11-14]. It is important to note 
that ICD devices should not be implanted in patients who 
exhibit NYHA class IV heart failure if they are not candi-
dates for transplantation, or those patients that are not ex-
pected to survive with adequate functional status for more 
than a year [12-15].  
  Despite these recommendations, however, ICD devices 
appear underutilized among candidates eligible for primary 
prevention of lethal arrhythmias [16-19]. Thus, for the pur-Predictors of Implantable Cardioverter-Defibrillator Use in Patients  The Open Cardiovascular Medicine Journal, 2010, Volume 4    207 
pose of this study we combined the above recommendations 
to evaluate the utilization of ICD therapy at our institution in 
patients with ischemic cardiomyopathy who have undergone 
coronary artery bypass grafting (CABG) surgery, with mild-
moderate heart failure symptoms, with left ventricular dys-
function (LVEF  35%). Patients who met these criteria 
were deemed to be eligible for primary prevention with an 
ICD. After determining ICD utilization at our center we at-
tempted to identify discrete patient characteristics that were 
independent predictors of receiving an ICD post surgical 
revascularization. Lastly, we also examined the long-term 
survival of eligible patients who received an ICD compared 
to eligible patients who did not receive a device. 
METHODS 
Patients 
  We examined all consecutive adult patients who under-
went surgical coronary revascularization (CABG) at the 
Queen Elizabeth II Health Sciences Center (QEII HSC) be-
tween March 1, 1995 and June 30, 2008. From this group, 
only patients with LVEF  35% were included. These pa-
tients were then divided into two groups: a ‘CABG + ICD’ 
group who received an ICD following CABG, and a ‘CABG 
only’ group who did not receive an ICD at any point in time 
during follow-up after CABG. Determination of LVEF was 
based on preoperative echocardiography, left ventricular 
angiography, and nuclear imaging when available. 
  Patients eligible for CABG surgery at our institution have 
traditionally been stratified based on a weekly peer review 
process involving cardiologists, cardiac surgeons, and car-
diac radiologists. Individual patients were queued for surgery 
based on objective criteria as previously described [20]. All 
patients were assigned the first available surgeon. Isolated 
CABG surgery was performed in 79% of patients. The re-
mainder of patients underwent a combination of CABG and 
other procedures, which include maze, aortic and mitral 
valve replacement or repair. 
  Patients were evaluated individually for the need for ICD 
therapy without a predetermined referral pattern. As such, 
patients were determined to be eligible on an individual basis 
following the recommendation from a group of collaborating 
electrophysiology specialists (EPS) practicing at the QEII 
HSC. Standard CCS criteria for ICD implantation were fol-
lowed [11, 14]. The types of ICD devices used at our institu-
tion were reflective of hospital contracts with the following 
manufacturers: Guidant, St. Jude, and Medtronic and in-
cluded single, dual, and bi-ventricular lead devices. All de-
vices were implanted in an operating room by a cardiovascu-
lar surgeon and an EPS physician 
Data Sources 
  The QEII HSC is the only tertiary care center in Nova 
Scotia, servicing over 1 million people, and is the site for all 
cardiac catheterization procedures and surgical interventions 
in the province. In a given year, over 1,200 adult cardiac 
surgeries are preformed at the QEII HSC. The Maritime 
Heart Center Cardiac Surgery Registry Database captures 
pre-operative, intra-operative, and in-hospital data from all 
CABG operations preformed in this province. 
  Data linkage between Maritime Heart Center Database 
and Population Health Research Unit (PHRU) at Dalhousie 
University was carried out using unique patient identifiers. 
Through PHRU we were able to access Nova Scotia Vital 
Statistics (mortality data) and the Canadian Institute for 
Health Information (CIHI) Discharge Abstract Database 
(DAD) to obtain all-cause mortality data and long-term fol-
low-up data for the patients in the present study. All data was 
reported as aggregate, which restricted access to individual 
patient information.  
Variable Selection 
  Patients were grouped based on age as follows: < 60, 60 
– 69, 70 – 79, > 80. Other pre-operative variables included, 
gender, smoking history, recent MI (MI < 7 days before 
CABG), hypertension, congestive heart failure, diabetes, 
peripheral vascular and cerebrovascular disease, chronic 
obstructive pulmonary disease, stenosis of the left main 
coronary artery > 50%, renal failure (pre-operative serum 
creatinine of > 176 mol/L), ventricular arrhythmia, severity 
of coronary artery disease (single versus double or left main 
disease versus triple), complexity of procedure (CABG alone 
versus CABG with additional procedures including valve or 
maze), incidence of redo surgery, and urgency of surgery. 
Urgency of surgery was determined and recorded at the time 
of surgery and was stratified as follows: Elective (stable, 
waiting at home), In-House Urgent (requiring hospitalization 
until the time of surgery), Urgent (requiring surgery within 
24 hours for symptoms or anatomy), and Emergent/Emergent 
Salvage (no delay, first available operating room).  
Statistical Analysis 
  Univariate analyses of pre-operative, intra-operative, and 
post-operative in-hospital variables was carried out using 
Chi-square tests for dichotomous variables, two tailed t-tests 
for normally distributed continuous variables, and Wilcoxon 
rank sum tests for continuous variables that were not   
normally distributed. Variables that were shown to exhibit 
difference between the ‘CABG + ICD’ and ‘CABG only’ 
groups as well as clinically relevant characteristics were ex-
amined as variables in multivariate logistic regression analy-
sis. Within the multivariate model an estimate was generated 
from each variable from which an odds ratio, p-value, and 
95% CI was calculated. A receiver operating characteristic 
curve was calculated as a measure of sensitivity and specific-
ity for our logistic regression model. Kaplan Meier survial 
curves for our ‘CABG + ICD’ and ‘CABG only’ groups were 
produced. A Cox proportional hazards ratio model was also 
produced to determine if ICD therapy was an independent 
predictor of improved survial. We included age, gender, pre-
op renal failure, arrhythmia, redo surgery, urgent or emergent 
status, chronic obstructive pulmonary disease (COPD), and 
cerebrovascular accident in our model in order to generate  
an adjusted hazard ratio. All statistical analysis was   
performed using SAS software version 9.1 (SAS, Cary, 
North Carolina).  
Data Validation Group 
  In a limited group of consecutive patients (2006-2007) 
we preformed a thorough chart review. The primary objec-
tive of this abstraction was to determine the rate of appropri-208    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Kelly et al. 
ate LVEF assessment post-revascularization. Second to this, 
we wanted to determine the number of patients who showed 
improvement in EF > 35% which, according to current 
guidelines, would negate their eligibility for primary preven-
tion with ICD therapy. 
RESULTS 
  Between March 1, 1995 and June 30, 2008 a total of 
1,169 out of 11,931 (9.8%) patients undergoing CABG sur-
gery in Halifax were found to have a pre-operative left ven-
tricular ejection fraction (LVEF) of  35% (mean LVEF = 
27.3% +/- 6.4%). These ischemic cardiomyopathy patients 
were defined as the ICD eligible group for the purpose of the 
present study. Of ICD eligible patients, 101 received an ICD 
some time after their CABG surgery (8.6%). Eight patients 
received an ICD prior to CABG and were excluded from   
the analysis. Patients were divided in 2 groups based on   
their eventual implantation of an ICD. Those that received  
an ICD (‘CABG + ICD’ group) were compared to those that 
did not (‘CABG only’ group). Patient demographics and co-
morbidities of the two groups are shown in Table 1. Patients 
who ultimately received ICD therapy were younger, more 
likely to be male, have a history of ventricular arrhythmias, 
Table 1.  Pre- and Intra-Operative Characteristics among CABG Patients with LVEF  35% 
Characteristic 
CABG + ICD 
n = 101 (%) 
CABG only 
n = 1068 (%) 
p -Value 
Age <60  39 (39)  262 (24) 
Age 60-69  36 (36)  328 (31) 
Age 70-79  23 (23)  369 (35) 
Age 80  3 (3)  109 (10) 
<0.01 
Female Gender  6 (6)  239 (22)  <0.01 
Smoking  85 (85)  817 (77)  0.08 
MI < 7d  13 (13)  172 (16)  0.47 
Hypertension   61 (60)  657 (62)  0.83 
CHF   54 (54)  624 (58)  0.34 
Diabetes   42 (42)  471 (44)  0.68 
PVD   25 (25)  274 (26)  0.91 
CVD   16 (16)  171 (16)  1.00 
COPD   14 (14)  268 (25)  0.01 
LM Stenosis >50%   24 (24)  278 (26)  0.72 
Renal Failure   7 (7)  164 (15)  0.02 
Ventricular Arrhythmia  37 (37)  83 (8)  <0.01 
Single Vessel Disease   1 (1)  54 (5) 
Double Vessel Disease  18 (18)  180 (17) 
Triple Vessel Disease   82 (82)  834 (78) 
0.18 
CABG Surgery Only  80 (79)  848 (79) 
CABG + Other Procedure  21 (21)  220 (21) 
1.00 
Redo  12 (12)  90 (8)  0.27 
Elective Status  34 (34)  297 (28) 
IHU Status  43 (42)  431 (40) 
Urgent Status  16 (16)  240 (23) 
Emergent Status  8 (8)  100 (9) 
0.35 
Smoking - includes past or present, MI - myocardial infarction, CHF - congestive heart failure, PVD -peripheral vascular disease, CVD - cerebrovascular disease, COPD - chronic 
obstructive pulmonary disease, Redo - reoperation for cardiac surgery, IHU - in hospital urgent, LVEF - Left ventricular ejection fraction. Predictors of Implantable Cardioverter-Defibrillator Use in Patients  The Open Cardiovascular Medicine Journal, 2010, Volume 4    209 
and were less likely have COPD or be in renal failure. In 
fact, only 6 of 245 eligible females with ischemic cardiomy-
opathy received an ICD during follow-up (2.4%).  
  Freedom from ICD implantation in eligible patients was 
95% at year 1, 93% at year 3, and 91% at year 5, suggesting 
low rates of utilization (Fig. 1). The median time to implant 
was 255 days post revascularization (IQR 14 - 1078 days) 
with 39% of patients receiving an ICD within 90 days of 
CABG surgery. This is in contrast to the increasing number 
of ICD implants performed in Halifax over the past decade 
(Fig. 2). Similarly, the proportion of ICD implants in patients 
with a history of surgical revascularization has also steadily 
increased over the same time period from 0% in 1997 to 
10.5% of all ICD implants in 2007. 
  A multivariate logistic regression analysis was used to 
correct differences between the ‘CABG + ICD’ and ‘CABG 
only’ groups and to identify predictors of ICD implantation 
in ischemic cardiomyopathy patients. A history of pre-
operative arrhythmia was the only variable found to inde-
pendently predict eventual ICD implantation (OR = 7.4; 95% 
confidence interval, 4.4-12.2) (Table 2). Independent vari-
ables that predicted patients not having an ICD implanted 
post CABG included having an urgent or emergent surgery 
on their original presentation (OR = 0.5; CI, 0.2-0.9), age > 
70 years (OR = 0.5; CI, 0.3-0.8), being female (OR = 0.2; 
CI, 0.1-0.6), or having COPD (OR = 0.5; CI, 0.3-0.8) (Table 
2). The receiver operating characteristic for the model was 
78%. 
  One should note that long-term follow up data for mortal-
ity analysis was available for 61 of our 101 patients. The 40 
patients lost to analysis failed to link to the Nova Scotia Vi-
tal Statistics Database as the majority of these were Maritime 
patients from outside of Nova Scotia. The survival benefit 
for patients with an ICD is illustrated in Fig. (3). Survival at 
1, 3 and 5 years was 95%, 89%, and 83% for the 
‘CABG+ICD’ group compared to 92%, 83% and 70% for 
the ‘CABG only’ group (log rank p = 0.02). At 5 years, pa-
tients who received an ICD had a relative risk reduction of 
death of 45%. Using Cox proportional hazards modeling, the 
unadjusted hazard ratio for ICD implantation was 0.49 (95% 
CI, 0.28-0.74; p = 0.02), and with adjustment, the hazard 
ratio decreased to 0.63 (95% CI, 0.33-1.20; p = 0.16). Fig. 
(4) shows adjusted survival: at 5 years post-CABG, survival 








Fig. (1). Freedom from implantable cardioverter defibrillator (ICD) implantation among coronary artery bypass grafting (CABG) patients 
with left ventricular ejection fraction (LVEF)  35% between March 1, 1995 and June 30, 2008. Incomplete mortality data. After 10 years 
237 of 1,169 cases were alive and without an ICD. Freedom from ICD implantation in eligible patients was 95% at year 1, 93% at year 3, 










Fig. (2). Annual implantable cardioverter-defibrillator (ICD) implantation rate stratified by ICD only and ICD in patients with a history of 
coronary artery bypass grafting (ICD+CABG) procedures. 210    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Kelly et al. 
pared to those who do not, respectively, according to the 
mean of covariates method which failed to reach signifi-
cance.  
  As a data validation step, a chart review of 80 consecu-
tive ICD eligible CABG patients between 2006-2007 re-
vealed that only 18 patients (22.5%) underwent EF assess-
ment  3 months after surgical revascularization despite cur-
rent recommendations. Of these 18 patients, 10 had persis-
tent LV dysfunction with EF  35% suggesting that a sig-
nificant proportion of revascularized patients may have in-
sufficient improvement in EF and therefore remain eligible 
(one of our criteria for eligibility). Based on these findings 
one could predict that more than 900 patients may not have 
had appropriate follow-up EF evaluation with as many as 
half of these patients exhibiting persistent LVEF dysfunction 
and as such remaining ICD eligible. 
DISCUSSION 
  In the present study we evaluated the utilization of ICD 
therapy in patients with ischemic cardiomyopathy, defined as 
those patients with a history of ischemic heart disease and an 
LVEF  35%, based on currently published guidelines [14-
15, 21]. Our entry criteria for ischemic heart disease, was 
based on having undergone surgical revascularization 
Table 2.  Risk Adjusted Odds Ratio Estimate of Variable Impact on Future ICD Implantation 
Patient Characteristic  OR Estimate  95% CI  P-Value 
Arrhythmia  7.4  4.4 - 12.2  <0.01 
Urgent or Emergent Status  0.5  0.2 - 0.9    0.01 
Age >70  0.5  0.3 - 0.8  <0.01 
Female Gender  0.2  0.1 - 0.6  <0.01 
COPD  0.5  0.3 - 0.8  <0.01 









Fig. (3). Kaplan Meier survival curves for implantable cardioverter-defibrillator (ICD) eligible coronary artery bypass graft (CABG) patients 
who received an ICD post-op (‘CABG+ICD’) and for those who do not (‘CABG only’ curve). At 5 years 83% of CABG+ICD patients are 








Fig. (4). Adjusted Cox proportional hazard model of survival in eligible patients who received ICD therapy (‘CABG+ICD’ curve) compared 
to those that did not (‘CABG only’ curve). Adjusted Hazard Ratio 0.63; 95% CI (0.33-1.20). Predictors of Implantable Cardioverter-Defibrillator Use in Patients  The Open Cardiovascular Medicine Journal, 2010, Volume 4    211 
(CABG) in Nova Scotia with patients identified using The 
Maritime Heart Center Cardiac Surgery Registry Database. 
This was not a review of all ischemic cardiomyopathy pa-
tients triaged at our institution but was specific to patients 
undergoing surgical revascularization. During our study pe-
riod extending from 1995-2008, a total of 1,169 consecutive 
patients were identified as ICD eligible. In this large group 
of eligible patients with 100% follow-up, only 101 (8.6%) 
patients received an ICD post surgical revascularization sug-
gesting low rates of ICD utilization. Freedom from ICD in 
this patient population was 95% at year 1, 93% at year 3, and 
91% at year 5 of follow-up illustrating the low rates of utili-
zation over time. Similar finding have been suggested by 
others who claim that ICD therapy is still vastly underutil-
ized among eligible candidates for primary prevention of 
lethal arrhythmias [16-19].  
  The retrospective nature of the study resulted in the un-
avoidable limitation that LVEF used to define eligibility was 
determined prior to revascularization. This limitation is 
based on evidence from published series that LVEF post-
CABG should improve, however, these findings may not 
necessarily be present or sufficient in all patients [22-24]. 
We have tried to address this limitation by retrospectively 
looking at a group of consecutive ICD eligible patients from 
2006 – 2007 and evaluated the documented changes in 
LVEF post-CABG. Using this approach we found that as 
few as 23% of patients underwent an EF assessment post-
CABG with less than half demonstrating improvement in 
LVEF above 35%. We speculate that if these findings were 
to be extrapolated to the remainder of the patient population, 
it is likely that a large proportion of patients included in the 
present study would remain ICD eligible post revasculariza-
tion. Furthermore, our data suggests that inadequate follow-
up evaluation of EF post revascularization may be one of the 
major reasons why patients are not considered for ICD ther-
apy. The rationale for looking at patient records from a small 
group of consecutive patients (n=80) was based on data ac-
cess limitations. The present study made use of large admin-
istrative data sets, which forbid access to individual patient 
information a pre-requisite for data encryption and linkage 
between data sets (confidentiality agreement for MHC-
PHRU linkage). Finally, while somewhat liberal, our ap-
proach in defining patient eligibility using administrative 
data in a large group of patients has been used by others sup-
porting our observations and approach [14].  
  The results of the CABG-Patch trial would suggest that 
underutilization of prophylactic ICD implantation among 
CABG patients with impaired LVEF is justified [25]. 
Briefly, this randomized control trial found no evidence of 
survival benefit when ICD implantation occurred at the time 
of CABG surgery in a population of eligible patients similar 
to those we examined. However, patients in the CABG-Patch 
trial were selected for ICD implantation on the basis of ‘ab-
normal signal averaged ECG changes’ compared to induc-
ible, sustained ventricular tachyarrhyhthmias in subsequent 
studies. After further investigation it was also found that a 
45% reduction in arrhythmic deaths after ICD implantation 
in the CABG-Patch trial was obscured by a high rate of non-
arrhythmic mortality [26]. Since the mid-1990s several other 
primary prevention trials have shown significant mortality 
risk reduction with ICD therapy in this patient population 
including the Multicenter Automatic Defibrillator Implanta-
tion Trial (MADIT) [5-9]. While our risk adjusted survival 
analysis was unable to support a survival advantage to ICD 
therapy once should note that we were also underpowered to 
make the conclusion that ICD are not beneficial. Therefore, 
it remains possible that ICD therapy in our patient popula-
tion could provide long-term survival benefit. 
  Using fully adjusted logistic regression analysis we were 
able to identify a single independent predictor of ICD utiliza-
tion, which was a history of arrhythmic events prior to re-
vascularization. This finding is in keeping with secondary 
prevention guidelines [11-15, 21]. We also identified 4 inde-
pendent variables that negatively predicted future ICD im-
plantation in our population of eligible patients. Our data 
suggests that female gender, patients over the age of 70, pa-
tients requiring emergent surgery at the time of CABG, and a 
history of severe lung disease were independently associated 
with a significantly reduced likelihood of ever receiving an 
ICD.  
  We are not the first to observe low ICD utilization among 
eligible women [16-19]. While some have speculated that 
women with ischemic disease have a lower incidence of 
SCD than men, explaining the lower rates of utilization, it 
has been shown that men and women with impaired left ven-
tricular function and ischemic disease receive similar sur-
vival benefit from ICD implantation [17, 19, 27]. Others 
have suggested that women are generally older then males at 
time of presentation, yet our multivariate analysis provided 
evidence that age alone cannot explain the discrepancy.  
  Several factors that are difficult to adjust might have con-
tributed to the low utilization of ICD therapy in elderly pa-
tients. Current guidelines suggest that ICD devices should be 
implanted in those patients who meet the criteria of impaired 
LVEF post-CABG and are expected to survive with adequate 
functional status for more than a year [12-15]. However, 
patients over 70 who present with ventricular dysfunction 
have the potential to be perceived by physicians as less ca-
pable of attaining adequate functional status in the future. As 
a result, device cost and resource allocation may be a plausi-
ble factor in the underutilization of ICD therapy in this 
group. 
  The present study was not designed to identify specific 
barriers to access. The evolution of clinical recommenda-
tions and practice guidelines between 1995 and 2008 make 
this nearly impossible in our study population. Unfortu-
nately, given the small number of patients receiving an ICD, 
it was also difficult to obtain meaningful data from examin-
ing utilization stratified by ICD recommendation eras. Nev-
ertheless, we provide strong evidence that ICD utilization is 
low post-CABG surgery in patients with ischemic cardiomy-
opathy. Furthermore, our findings suggest that a lack of fol-
low-up assessment of LVEF post surgical revascularization 
(fewer than 23% assessed) may explain why patients are not 
considered eligible for ICD despite clear guidelines suggest-
ing follow-up evaluation.  
CONCLUSIONS 
  Despite the above limitations we provide data from a 
large Canadian registry looking at patients with coronary 
artery disease and impaired LV function, many of which are 212    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Kelly et al. 
eligible for ICD implantation post surgical revascularization. 
We provide valuable every-day clinical practice information 
suggesting low rates of ICD utilization (< 10%) with age and 
gender inequalities among several sub-groups of ICD eligi-
ble patients. Based on our findings, LVEF assessment post 
revascularization may be as low at 23% and may represent a 
mechanism explaining why patients are not considered for 
ICD therapy.  
ABBREVIATIONS 
SCD   =  Sudden Cardiac Death 
ICD =  Implantable  cardioverter-defibrillator 
VF =  Ventricular  Fibrillation 
VT =  Ventricular  Tachycardia 
CCS  =  Canadian Cardiovascular Society 
LVEF  =  Left Ventricular Ejection Fraction 
MI =  Myocardial  Infarction 
NYHA  =  New York Heart Association 
CABG  =  Coronary Artery Bypass Grafting 
QEII HSC  =  Queen Elizabeth II Health Sciences Center 
EPS =  Electrophysiology  Specialist 
PHRU  =  Population Health Research Unit 
CIHI  =  Canadian Institute for Health Information 
DAD  =  Discharge Abstract Database 
MADIT  =  Multicenter Automatic Defibrillator   
Implantation Trial 
COMPETING INTERESTS 
The authors of this manuscript have no competing interests 
to disclose 
AUTHORS CONTRIBUTIONS 
RK carried out the study design and drafted the manuscript. 
KB carried out the statistical analysis. OH participated in the 
data collection and participated in drafting the manuscript. 
MB was involved with the study design and editing manu-
script. JFL conceived of the study, and participated in its 
design and coordination and helped to draft the manuscript. 
All authors read and approved the final manuscript. 
REFERENCES 
[1]  DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med 
2003; 349: 1836-47. 
[2]  Goldenberg I, Moss AJ. Implantable device therapy. Prog Cardio-
vasc Dis 2008; 50: 449-4. 
[3]  Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, 
mechanisms, and therapy. Curr Probl Cardiol 2007; 32: 501-46. 
[4]  Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the 
implantable cardioverter defibrillator secondary prevention trials. 
AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable 
Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Im-
plantable Defibrillator Study. Eur Heart J 2000; 21: 2071-8. 
[5]  Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an 
implanted defibrillator in patients with coronary disease at high   
risk for ventricular arrhythmia. Multicenter Automatic Defibrillator 
Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-
40. 
[6]  Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a 
defibrillator in patients with myocardial infarction and reduced 
ejection fraction. N Engl J Med 2002; 346: 877-83. 
[7]  Goldenberg I, Moss AJ, McNitt S, et al. Time dependence of defi-
brillator benefit after coronary revascularization in the Multicenter 
Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll 
Cardiol 2006; 47: 1811-7. 
[8]  Al-Khatib SM, Hellkamp AS, Lee KL, et al. Implantable   
cardioverter defibrillator therapy in patients with prior coronary   
revascularization in the Sudden Cardiac Death in Heart Failure 
Trial (SCD-HeFT). J Cardiovasc Electrophysiol 2008; 19: 1059-65. 
[9]  Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an 
implantable cardioverter-defibrillator after acute myocardial infarc-
tion. N Engl J Med 2004; 351: 2481-8. 
[10]  Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator 
implantation in patients with nonischemic dilated cardiomyopathy. 
N Engl J Med 2004; 350: 2151-8. 
[11]  Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Soci-
ety consensus conference recommendations on heart failure 2006: 
diagnosis and management. Can J Cardiol 2006; 22: 23-45. 
[12]  Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 
guidelines for management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death: a report of the Ameri-
can College of Cardiology/American Heart Association Task Force 
and the European Society of Cardiology Committee for Practice 
Guidelines (Writing Committee to Develop Guidelines for Man-
agement of Patients With Ventricular Arrhythmias and the Preven-
tion of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48: e247-
346. 
[13]  Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 
2008 Guidelines for Device-Based Therapy of Cardiac Rhythm 
Abnormalities: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Practice Guide-
lines (Writing Committee to Revise the ACC/AHA/NASPE 2002 
Guideline Update for Implantation of Cardiac Pacemakers and 
Antiarrhythmia Devices) developed in collaboration with the 
American Association for Thoracic Surgery and Society of Tho-
racic Surgeons. J Am Coll Cardiol 2008; 51: e1-62. 
[14]  Howlett JG, McKelvie RS, Arnold JM, et al. Canadian Cardiovas-
cular Society Consensus Conference guidelines on heart failure, 
update 2009: diagnosis and management of right-sided heart fail-
ure, myocarditis, device therapy and recent important clinical trials. 
Can J Cardiol 2009; 25: 85-105. 
[15]  Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 
2002 Guideline Update for Implantation of Cardiac Pacemakers 
and Antiarrhythmia Devices--summary article: a report of the 
American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (ACC/AHA/NASPE Committee to 
Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol 2002; 
40: 1703-19. 
[16]  Udell JA, Juurlink DN, Kopp A, Lee DS, Tu JV, Mamdani MM. 
Inequitable distribution of implantable cardioverter defibrillators in 
Ontario. Int J Technol Assess Health Care 2007; 23: 354-61. 
[17]  Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, 
Schulman KA. Sex differences in the use of implantable   
cardioverter-defibrillators for primary and secondary prevention of 
sudden cardiac death. JAMA 2007; 298: 1517-24. 
[18]  Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial   
differences in the use of implantable cardioverter-defibrillators 
among patients hospitalized with heart failure. JAMA 2007; 298: 
1525-32. 
[19]  Yarnoz MJ, Curtis AB. Sex-based differences in cardiac resyn-
chronization therapy and implantable cardioverter defibrillator 
therapies: effectiveness and use. Cardiol Rev 2006; 14: 292-8. 
[20]  Legare JF, MacLean A, Buth KJ, Sullivan JA. Assessing the risk of 
waiting for coronary artery bypass graft surgery among patients 
with stenosis of the left main coronary artery. CMAJ 2005; 173: 
371-5. 
[21]  Tang AS, Ross H, Simpson CS, et al. Canadian Cardiovascular 
Society/Canadian Heart Rhythm Society position paper on im-
plantable cardioverter defibrillator use in Canada. Can J Cardiol 
2005; 21 Suppl A: 11A-8A. 
[22]  Soliman Hamad MA, Tan ME, van Straten AH, van Zundert AA, 
Schonberger JP. Long-term results of coronary artery bypass graft-Predictors of Implantable Cardioverter-Defibrillator Use in Patients  The Open Cardiovascular Medicine Journal, 2010, Volume 4    213 
ing in patients with left ventricular dysfunction. Ann Thorac Surg 
2008; 85: 488-93. 
[23]  Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left   
ventricular ejection fraction, heart failure symptoms and prognosis 
after revascularization in patients with chronic coronary artery   
disease and viable myocardium detected by dobutamine stress 
echocardiography. J Am Coll Cardiol 1999; 34: 163-9. 
[24]  Elefteriades JA, Tolis G Jr, Levi E, Mills LK, Zaret BL. Coronary 
artery bypass grafting in severe left ventricular dysfunction: excel-
lent survival with improved ejection fraction and functional state. J 
Am Coll Cardiol 1993; 22: 1411-7. 
[25]  Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in 
patients at high risk for ventricular arrhythmias after coronary-
artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) 
Patch Trial Investigators. N Engl J Med 1997; 337: 1569-75. 
[26]  Bigger JT Jr, Whang W, Rottman JN, et al. Mechanisms of   
death in the CABG Patch trial: a randomized trial of implantable 
cardiac defibrillator prophylaxis in patients at high risk of death af-
ter coronary artery bypass graft surgery. Circulation 1999; 99: 
1416-21. 
[27]  Zareba W, Moss AJ, Jackson Hall W, et al. Clinical course and 
implantable cardioverter defibrillator therapy in postinfarction 
women with severe left ventricular dysfunction. J Cardiovasc   
Electrophysiol 2005; 16: 1265-70. 
 
 
Received: September 16, 2010  Revised: October 13, 2010  Accepted: October 15, 2010 
 
© Kelly et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.  
 
 